The agency has granted priority review to SH-111, Shorla’s mystery candidate for the third-line treatment of adults and children with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), the company said on Friday.
Ryan, Shorla’s CTO, told Endpoints News that the candidate is a new take on a standard-of-care treatment which she says is in short supply, but declined to comment any further. While most leukemias target older people, T-cell leukemia is an aggressive blood and bone marrow cancer that’s most common among children.
Read more at: https://endpts.com/shorla-pharma-scores-an-expedited-review-for-its-mystery-candidate-to-treat-t-cell-malignancies/
